Exact Sciences Gets Compliance Warning Letter from Nasdaq

A little more than a month after inking a deal with Genzyme that will provide the firm with a $24.5 million cash infusion, Exact Sciences has been told by Nasdaq that it is not in compliance with a listing regulation.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.